

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 47/34	A1	(11) International Publication Number: WO 95/25545 (43) International Publication Date: 28 September 1995 (28.09.95)
(21) International Application Number: PCT/EP95/00973 (22) International Filing Date: 15 March 1995 (15.03.95) (30) Priority Data: P 44 09 357.8 18 March 1994 (18.03.94) DE (71)(72) Applicants and Inventors: SCHMIDT, Alfred [DE/DE]; Leinpfad 2, D-22301 Hamburg (DE). UPMEYER, Hans- Jürgen [DE/DE]; Mauerkircherstrasse 197, D-81925 München (DE). (74) Agent: VOSSIUS & PARTNER; Siebertstrasse 4, D-81675 München (DE).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: THE USE OF DIMETICONE AS A TRANSPORT AND CARRIER SYSTEM AND/OR DRUG DELIVERY SYSTEM		
(57) Abstract The invention relates to dimethylpolysiloxane (dimeticone) to be used as a transport and carrier system and/or a drug delivery system for pharmaceutical drugs. Moreover, the invention relates to pharmaceutical compositions containing dimethylpolysiloxane as a transport and carrier system and/or as a drug delivery system in combination with an active ingredient.		

BEST AVAILABLE COPY

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

The Use of Dimeticone as a Transport and Carrier System
and/or Drug Delivery System

TECHNICAL FIELD OF THE INVENTION

The invention relates to dimethylpolysiloxane (dimeticone) to be used as a transport and carrier system and/or a drug delivery system for pharmaceutical drugs for instance for the treatment of gastro-intestinal diseases. Moreover, the invention relates to pharmaceutical compositions containing dimethylpolysiloxane as a transport and carrier system and/or as a drug delivery system in combination with an active ingredient and methods related thereto.

Commercial dimeticone-containing preparations are used to treat symptoms such as flatulence, sensation of repletion (bloating) and meteorism. Moreover, the use of dimeticone for treating inflammatory and ulcerous diseases of the esophagus, the stomach and the duodenum has been described.

BACKGROUND OF THE INVENTION

In order to avoid dose-related side effects, the galenics of a pharmaceutical composition should be such that only the

dose of the active ingredient necessary to elicit the desired therapeutic effect needs to be administered.

Hence, it is desirable to apply the therapeutically active ingredient right at the site where it is to produce its effect or at the site where it is absorbed so as to increase the local bioavailability and/or general bioavailability of the active ingredient (for instance by averting a first pass effect in the liver) or so as to avoid systemic side effects as much as possible.

In view of the different physiological properties of the different sections of the gastro-intestinal tract (GI tract), local therapy is particularly difficult in this case.

The continuous peristalsis, the variation of the chemical conditions over the length of the digestive tract, and the morphology of the surface of the GI tract are obstacles to a prolonged residence time in the different sections of the tract (such as the esophagus, stomach, duodenum, and colon).

Especially in the case of chronic diseases, such as inflammatory, infectious, ulcerous or neoplastic changes of the GI tract, direct local therapy capable of being continued over a prolonged period of time is desirable.

Furthermore, local treatment is also desirable in the case of disorders in the cardiovascular system, the lungs, the brain, and all hollow organs.

Local treatment requires a suitable transport and carrier system and/or drug delivery system.

SUMMARY OF THE INVENTION

The present invention provides a carrier that lends itself for use in particular galenic pharmaceutical forms for oral, rectal and intraoperative applications which release and/or fix the active ingredient continuously at the very site where it is to produce its effect or is absorbed.

It was surprisingly found that dimeticone, because of its unique physico-chemical properties is ideally suited for such purposes. Dimeticone has a very wide range of viscosities, depending on the degree of polymerization. The viscosity of dimeticone to be used in accordance with the invention may vary, depending on the therapeutical purpose, the nature and location of the condition to be treated as well as the drug to be administered. Preferably, dimeticone having a kinematic viscosity in the range of 10 to 100,000 $\text{mm}^2 \cdot \text{s}^{-1}$ is used.

The use of dimeticone having a kinematic viscosity in the range of 300 to 1,500 $\text{mm}^2 \cdot \text{s}^{-1}$ is particularly preferred. Dimeticone may also be supplemented with silicone dioxide as it is for example contained in the product Simeticone.

Dimeticone was found to show a particular association with or affinity to the surface structure of the GI tract. Because of an increased adhesion resulting from the adhesive properties of dimeticone, the residence time of an active ingredient in a region of the GI tract can be substantially prolonged if dimeticone is used as a transport or carrier system.

However, because of the different chemical, morphological and physiological conditions along the GI tract, the affinity and association of dimeticone with the epithelial cells of the GI tract is not uniform. Thus, in order to

optimize the effect of dimeticone as a transport and carrier system and/or drug delivery system for any particular drug at any particular site of the GI tract, dimeticone with the appropriate viscosity should be chosen, depending on the nature of the therapy and drug as well as the location in the GI tract. This may readily be determined by experimentation.

The use of dimeticone is not limited to the treatment of the GI tract. It may also be used in the treatment of the cardiovascular system the lungs, the brain and all hollow organs.

According to the invention, dimeticone was found to be particularly suitable as a transport and carrier system or a drug delivery system for cytostatic drugs, immunosuppressants, immunomodulating and immunostimulative substances, biological response modifying (BRM) substances, radio-, chemo- and photosensitizers, anti-inflammatory substances, such as corticoids, antibiotics, analgesics, locally effective anesthetics, antiphlogistics, non-steroidal antirheumatics, antiviral substances, bismuth preparations and motility inhibiting and motility enhancing substances.

The function of dimeticone as a carrier for the photosensitizer δ -amino levulinic acid (ALA), the H_2 antagonists (such as ranitidine and cimetidine) and the proton pump inhibitors (such as omeprazole and lansoprazole) is particularly preferred.

The pharmaceutical compositions which contain dimeticone in combination with one of the afore-mentioned substances therefore lend themselves particularly well for the treatment of inflammatory, infectious, ulcerous and neoplastic diseases of the GI tract.

In the treatment of disorders in the lower area of the GI tract, the dimeticone-containing pharmaceutical composition may be formulated in an enteral form according to conventional methods in order to prevent dimeticone and the active ingredient from remaining in the upper zone of the GI tract. Alternatively, the properties of the pharmaceutical composition should be so adjusted that it has an increased affinity for the lower part of the GI tract.

Direct application, for instance via the bioptic channel of an endoscope, bronchoscope or proctoscope, intraoperative or by instillation, is particularly preferred.

The dimeticone-containing pharmaceutical composition should also contain highly dispersed silicon dioxide and/or a pharmaceutically acceptable surface-active agent.

The ratio of dimethylpolysiloxane to the surface-active agent is preferably 3 to 10 : 1, in particular 4 to 6 : 1, and the ratio of highly dispersed silicon dioxide to dimethylpolysiloxane is preferably 3 to 50% (wt/wt). A preferred range for the latter ratio is 30 to 40% (wt/wt), the value of 35 to 36% being particularly preferred.

The concentration of the surface active agent is preferably at least 1.5 % (wt/wt). A particularly preferred dimeticone formulation contains 8-10% (wt/wt) of the surface active agent.

Stearic salts or long chain alkanolic acids, in particular C_{11} - C_{18} alkanolic acids, such as myristic acid, palmitic acid and stearic acid, and their salts, such as magnesium or calcium salts and mixtures thereof can be suitably used as pharmaceutically acceptable surface active agents.

The invention is illustrated by the following example.

Example **δ -amino levulinic acid containing emulsion (ALA)**

	amount/dose mg / 250 ml
ALA	5,000.0000
simeticone (dimeticone 1000 - SiO ₂ 94:6)	2,000.0000
Aerosil 200	125.0000
Kollidon CL M ¹	2,500.0000
hydroxyethylcellulose	20,000.0000
Veegum K ²	2,500.0000
cinnamon oil DA B 10	0.1228
85% indigotin	0.0250
water, purified	ad 250 ml

1 = polyvinylpyrrolidone (INN: providone)

2 = colloidal magnesium = aluminum silicate

The emulsion of the Example is intended for the photodynamic therapy of tumors of the GI tract, the emulsion being applied by means of an endoscope at the very site where the effect is to be elicited.

While we have described an embodiment of this invention, it is apparent that our embodiment may be altered to provide other embodiments which utilize the method of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims, rather than by the specific embodiment which has been presented by way of example.

We Claim:

1. The use of dimethylpolysiloxane as a transport or carrier system for active ingredients for the preparation of a pharmaceutical composition.
2. A pharmaceutical composition containing dimethylpolysiloxane in combination with a photosensitizer.
3. The pharmaceutical composition according to claim 2 wherein the photosensitizer is δ -amino levulinic acid ALA.
4. A pharmaceutical composition containing dimethylpolysiloxane in combination with an H_2 -antagonist and/or a proton pump inhibitor.
5. A pharmaceutical composition containing dimethylpolysiloxane in combination with one or more antibiotics.
6. A pharmaceutical composition containing dimethylpolysiloxane in combination with an immunomodulating substance or an immunostimulating substance.
7. A pharmaceutical composition containing dimethylpolysiloxane in combination with an analgesic or locally effective anesthetic.
8. A pharmaceutical composition containing dimethylpolysiloxane in combination with an antiphlogistic or non-steroidal antirheumatic.
9. A pharmaceutical composition containing dimethylpolysiloxane in combination with an anti-viral substance.

10. The use according to claim 1, wherein the active ingredient is a corticoid.
11. A pharmaceutical composition containing dimethylpoly-siloxane in combination with a bismuth preparation.
12. A pharmaceutical composition containing dimethylpoly-siloxane in combination with a motility-inhibiting or motility-enhancing substance.
13. A pharmaceutical composition containing dimethylpoly-siloxane in combination with BRM (biological response modifying) substances.

INTERNATIONAL SEARCH REPORT

 Inter national Application No
 PCT/EP 95/00973

 A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61K47/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,5 229 137 (M. MICHAEL WOLFE) 20 July 1993 see claims 13-18,24,25 ---	1,4,13
X	US,A,4 837 029 (JAMES L. OLSEN) 6 June 1989 see claim 1 ---	1,5,13
X	EP,A,0 219 076 (SUMITOMO PHARMACEUTICALS) 22 April 1987 see claims 1,2,5,9 see column 2, line 29 - column 4, line 42 ---	1,6,9,13
X	FR,A,2 110 314 (ISTITUTO DE ANGELI S.P.A.) 2 June 1972 see claims 1,4 --- -/--	1,7,13



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

4 July 1995

Date of mailing of the international search report

20.07.95

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+ 31-70) 340-3016

Authorized officer

Ventura Amat, A

INTERNATIONAL SEARCH REPORT

Inter^{nat.} Application No

PCT/EP 95/00973

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,94 03209 (MERCK & CO.) 17 February 1994 see claim 1 ---	1,8,13
X	WO,A,91 04034 (PEHROM PHARMACEUTICAL CORPORATION) 4 April 1991 see page 22; claims 5,6,9,15-20 see page 4, line 16 - line 25 ---	1,10,13
X	FR,M,3 848 (ROBERT SHAPIRO) 17 January 1966 see the whole document ---	1,11,13
X	EP,A,0 428 296 (MCNEIL-PPC) 22 May 1991 see claims 1,2 see page 3, line 32 - line 38 ---	1,11-13
P,A	WO,A,95 05813 (NOVEN PHARMACEUTICALS) 2 March 1995 see claims 1,6 -----	1-3,13

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 95/00973

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-5229137	20-07-93	AU-B- 4225093 WO-A- 9321932	29-11-93 11-11-93
US-A-4837029	06-06-89	NONE	
EP-A-0219076	22-04-87	AU-B- 594088 AU-A- 6385486 DE-A- 3684220 ES-T- 2051682 US-A- 4985253 JP-A- 62174031 JP-A- 62174007	01-03-90 16-04-87 16-04-92 01-07-94 15-01-91 30-07-87 30-07-87
FR-A-2110314	02-06-72	GB-A- 1357737 CA-A- 974883 DE-A- 2149699 SE-B- 382560 US-A- 3853988	26-06-74 23-09-75 13-04-72 09-02-76 10-12-74
WO-A-9403209	17-02-94	AU-B- 4682193	03-03-94
WO-A-9104034	04-04-91	AU-A- 6417690 CN-A- 1050502	18-04-91 10-04-91
FR-M-3848		NONE	
EP-A-0428296	22-05-91	AT-T- 106737 AU-B- 634833 AU-A- 6569190 CA-A- 2029015 DE-D- 69009684 DE-T- 69009684 ES-T- 2058815 GR-A- 90100785 JP-A- 3206048 US-A- 5248505	15-06-94 04-03-93 09-05-91 02-05-91 14-07-94 06-10-94 01-11-94 17-04-92 09-09-91 28-09-93
WO-A-9505813	02-03-95	AU-B- 7672294	21-03-95